Skip to main content

6 Result(s)

within T Caravita Remove this filter Cancer Research Remove this filter

and

  1. No Access

    Article

    Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis

    In newly diagnosed myeloma patients, upfront autologous transplant (ASCT) prolongs progression-free survival 1 (PFS1) compared with chemotherapy plus lenalidomide (CC+R). Salvage ASCT at first relapse may stil...

    F Gay, S Oliva, M T Petrucci, V Montefusco, C Conticello, P Musto, L Catalano… in Leukemia (2017)

  2. No Access

    Article

    A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma

    This phase 2 trial evaluated three low-dose intensity subcutaneous bortezomib-based treatments in patients ⩾75 years with newly diagnosed multiple myeloma (MM). Patients received subcutaneous bortezomib plus o...

    A Larocca, S Bringhen, M T Petrucci, S Oliva, A P Falcone, T Caravita… in Leukemia (2016)

  3. No Access

    Article

    Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia

    P Musto, V Simeon, M C Martorelli, M T Petrucci, N Cascavilla, F Di Raimondo… in Leukemia (2014)

  4. Article

    Open Access

    Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom's macroglobulinemia: a retrospective multicentric study

    Bisphosphonates (BPs) are used intravenously to treat cancer-related conditions for the prevention of pathological fractures. Osteonecrosis of the jaw (BRONJ) is a rare complication reported in 4–15% of patien...

    A Andriani, M T Petrucci, T Caravita, M Montanaro, N Villivà… in Blood Cancer Journal (2012)

    Download PDF (414 KB) View Article

  5. No Access

    Article

    Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy

    Lenalidomide has raised concerns regarding its potential impact on the ability to collect stem cells for autologous stem cell transplantation, especially after prolonged exposure. The use of cyclophosphamide p...

    F Cavallo, S Bringhen, G Milone, D Ben-Yehuda, A Nagler, E Calabrese… in Leukemia (2011)

  6. No Access

    Article

    Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)

    Several trials have shown the superior impact of high-dose melphalan (usually 200 mg/m2, MEL200) vs standard therapy in myeloma patients. Intermediate-dose melphalan (100 mg/m2, MEL100) is also superior to the st...

    A Palumbo, S Bringhen, A Bertola, F Cavallo, P Falco, M Massaia, B Bruno, C Rus… in Leukemia (2004)